Cargando…

Case Report: Adult Still’s Disease in an Alemtuzumab-Treated Multiple Sclerosis Patient

BACKGROUND: Autoimmune adverse events are the most relevant risks of alemtuzumab therapy. We present a patient with relapsing-remitting multiple sclerosis, who developed adult-onset Still’s disease (AOSD) following alemtuzumab treatment. CASE PRESENTATION: The patient suffered from sore throat, swal...

Descripción completa

Detalles Bibliográficos
Autores principales:	Krämer, Julia, Krömer-Olbrisch, Tanja, Lakomek, Heinz-Jürgen, Schellinger, Peter D., Foell, Dirk, Meuth, Sven G., Straeten, Vera
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7493652/ https://www.ncbi.nlm.nih.gov/pubmed/33013884 http://dx.doi.org/10.3389/fimmu.2020.02099

Ejemplares similares

Alemtuzumab in Multiple Sclerosis: Short- and Long-Term Effects of Immunodepletion on the Peripheral Treg Compartment
por: Haas, Jürgen, et al.
Publicado: (2019)

Alemtuzumab in Multiple Sclerosis: Mechanism of Action and Beyond
por: Ruck, Tobias, et al.
Publicado: (2015)

Long-term efficacy of alemtuzumab in polymyositis
por: Ruck, Tobias, et al.
Publicado: (2015)

Event-Driven Immunoprofiling Predicts Return of Disease Activity in Alemtuzumab-Treated Multiple Sclerosis
por: Akgün, Katja, et al.
Publicado: (2020)

A case of idiopathic multicentric Castleman disease in an alemtuzumab-treated patient with MS
por: Rolfes, Leoni, et al.
Publicado: (2019)

Alemtuzumab Improves Cognitive Processing Speed in Active Multiple Sclerosis—A Longitudinal Observational Study
por: Riepl, Ester, et al.
Publicado: (2018)

Impact of previous disease-modifying treatment on effectiveness and safety outcomes, among patients with multiple sclerosis treated with alemtuzumab
por: Pfeuffer, Steffen, et al.
Publicado: (2021)

Impact of FcγR variants on the response to alemtuzumab in multiple sclerosis
por: Keller, Christian W., et al.
Publicado: (2019)

Alemtuzumab treatment alters circulating innate immune cells in multiple sclerosis
por: Gross, Catharina C., et al.
Publicado: (2016)

Alemtuzumab for Multiple Sclerosis
por: Willis, Mark D., et al.
Publicado: (2016)

Immune Regulatory Cell Bias Following Alemtuzumab Treatment in Relapsing-Remitting Multiple Sclerosis
por: Kashani, Nicole, et al.
Publicado: (2021)

Alemtuzumab in the treatment of multiple sclerosis
por: Fernandez, Óscar
Publicado: (2014)

Alemtuzumab for the treatment of multiple sclerosis
por: Willis, Mark D, et al.
Publicado: (2015)

Linking Microstructural Integrity and Motor Cortex Excitability in Multiple Sclerosis
por: Radetz, Angela, et al.
Publicado: (2021)

Long-Term Effects of Alemtuzumab on CD4+ Lymphocytes in Multiple Sclerosis Patients: A 72-Month Follow-Up
por: Rolla, Simona, et al.
Publicado: (2022)

Role of B Cell Profile for Predicting Secondary Autoimmunity in Patients Treated With Alemtuzumab
por: Walo-Delgado, Paulette Esperanza, et al.
Publicado: (2021)

The role of iron metabolism in the pathogenesis and treatment of multiple sclerosis
por: Duarte-Silva, Eduardo, et al.
Publicado: (2023)

Selective Brain Network and Cellular Responses Upon Dimethyl Fumarate Immunomodulation in Multiple Sclerosis
por: Ciolac, Dumitru, et al.
Publicado: (2019)

Alemtuzumab therapy changes immunoglobulin levels in peripheral blood and CSF
por: Möhn, Nora, et al.
Publicado: (2019)

Monitoring and management of autoimmunity in multiple sclerosis patients treated with alemtuzumab: practical recommendations
por: Devonshire, Virginia, et al.
Publicado: (2018)

Potential COVID-19 infection in patients with severe multiple sclerosis treated with alemtuzumab
por: Matías-Guiu, Jorge, et al.
Publicado: (2020)

Endocrine and multiple sclerosis outcomes in patients with autoimmune thyroid events in the alemtuzumab CARE-MS studies
por: Dayan, Colin M., et al.
Publicado: (2023)

Early and Degressive Putamen Atrophy in Multiple Sclerosis
por: Krämer, Julia, et al.
Publicado: (2015)

The adenosinergic signaling in the pathogenesis and treatment of multiple sclerosis
por: Duarte-Silva, Eduardo, et al.
Publicado: (2022)

Management of immune thrombocytopenia in multiple sclerosis patients treated with alemtuzumab: a Belgian consensus
por: Lambert, Catherine, et al.
Publicado: (2018)

Trans-Endothelial Migration of Memory T Cells Is Impaired in Alemtuzumab-Treated Multiple Sclerosis Patients
por: Nguyen, Kristy, et al.
Publicado: (2022)

An observational study of alemtuzumab following fingolimod for multiple sclerosis
por: Willis, Mark, et al.
Publicado: (2017)

Role of Monoclonal Antibody "Alemtuzumab" in the Treatment of Multiple Sclerosis
por: Nosher, Sadia, et al.
Publicado: (2021)

Effects of Alemtuzumab on (Auto)antigen-Specific Immune Responses
por: Hilger, Clara, et al.
Publicado: (2020)

Combined Neurofilament Light and Optical Coherence Tomography Better Predicts Multiple Sclerosis Disease Activity Than Either Measure Alone
por: Krämer, Julia, et al.
Publicado: (2021)

COVID-19 and multiple sclerosis: A description of two cases on alemtuzumab
por: Fernández-Díaz, Eva, et al.
Publicado: (2020)

Mucosal-Associated Invariant T Cells in Multiple Sclerosis: The Jury is Still Out
por: Treiner, Emmanuel, et al.
Publicado: (2015)

Short-term outcomes of pediatric multiple sclerosis patients treated with alemtuzumab at a Canadian University multiple sclerosis clinic
por: Jure Hunt, David, et al.
Publicado: (2020)

Immune thrombocytopenia in alemtuzumab-treated MS patients: Incidence, detection, and management
por: Cuker, Adam, et al.
Publicado: (2019)

Thyroid disorders in alemtuzumab-treated multiple sclerosis patients: a Belgian consensus on diagnosis and management
por: Decallonne, Brigitte, et al.
Publicado: (2018)

Alemtuzumab: evidence for its potential in relapsing—remitting multiple sclerosis
por: Brown, JWL, et al.
Publicado: (2013)

Comparative efficacy of alemtuzumab and established treatment in the management of multiple sclerosis
por: Babij, Rachel, et al.
Publicado: (2015)

Intractable and highly active relapsing multiple sclerosis – role of alemtuzumab
por: Dubey, Divyanshu, et al.
Publicado: (2015)

Alemtuzumab in the treatment of multiple sclerosis: patient selection and special considerations
por: Dörr, Jan, et al.
Publicado: (2016)

Autoimmune thyroid disease following treatment with alemtuzumab for multiple sclerosis
por: Alamo, Angela, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_292un65ulnre4g6j4khn5d49or